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OBJECTIVES: To determine the effect of enrollment in a prescription drug plan on
use of controller medications in patients with persistent asthma. METHODS: The
study used a retrospective, cross sectional research design. The data source uti-
lized was the 2008 Medical Expenditure Panel Survey (MEPS), a nationally repre-
sentative sample of the non-institutionalized, civilian U.S. population. Analysis
was restricted to asthma patients who reported use of more than 3 canisters of
rescue inhalers in a three-month period. Controller medication use was self-re-
ported byMEPS respondants. Descriptive statisticswas used to describe the sample
and their controller medication use. A logistic regressionmodel was used to assess
the effect of prescription drug coverage based on the type of prescription drug plan
on the controller medication use while adjusting for age, gender, race, ethnicity,
income and perceived health status. All analyses were carried out using SASv.9.1.
RESULTS: Forty-two percent of respondents had prescription drug coverage while
67% reported use of controller medications. In the regression model, controller
medication use was found to be similar amongst patients with prescription drug
coverage and patients without coverage (68%, 66%, respectively). Patients with
prescription drug coverage were less likely to use controller medications than
those who did not have coverage, although this effect was not significant (OR 
0.53,CI:0.28-1.01). Patients with Medicare (OR 4.35, CI:1.61-11.75), Medicaid (OR
5.44, CI:2.23-13.24) or Veterans Affairs (OR  12.82, CI:3.21-51.16) prescription cov-
erageweremore likely to use controllermedicationswhen comparedwith patients
in other types of plans. Both pediatric patients (OR  5.51, CI:1.27-23.88) and pa-
tients with excellent perceived health status (OR 5.10, CI:2.04-12.76) had a higher
likelihood of using controller medications. CONCLUSIONS: Enrollment in a pre-
scription drug plan did not show a significant impact on use of controller medica-
tions. However, enrollment in Medicare, Medicaid or Veterans Affairs prescription
plans increased likelihood of controller medication use in this patient cohort.
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OBJECTIVES: The exposure to biofuel smoke is a risk factor for Chronic Obstructive
Pulmonary Disease –COPD- while using natural gas may be protective against it.
There is few evidence from Latin America on the relationship between use of
different types of fuels to cook and respiratory diseases. The present report is
aimed to assess differences in the prevalence of abnormalities to respiratory func-
tions between populations who used biomass fuel to cook against those using
cleaner sources of energy such as natural gas.METHODS: A cross-sectional popu-
lation based study was designed to evaluate the respiratory function, through spi-
rometry, in subjects cooking with biomass or natural gas. All patients were evalu-
ated by a general physician and a pulmonologist. We compared the prevalence of
spirometry abnormalities on those cooking with natural gas versus those cooking
with biomass fuel. A multivariable logistic regression was used to adjust differ-
ences by potential confounding factors. RESULTS: Overall 203 persons were stud-
ied. After adjusting by potential confounders there were a significant increase in
the prevalence of severe obstructive pattern (OR 5.50; 95% CI 1.17-25.79) in subjects
who cookwith biomass comparedwith natural gas users. Values of Forced Expired
Volume in one second (FEV1) and forced vital capacity (FVC) were lower among
those cooking with biomass. The differences in prevalence of respiratory mor-
bidity and symptoms were not statistically significant between both groups.
CONCLUSIONS: These findings suggest that replacing biomass fuel by natural gas
may be an important public health intervention in Colombia because it can reduce
the prevalence of abnormal patterns of pulmonary function.
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OBJECTIVES: The 2006 guidelines of the American Academy of Family Physicians
recommends to avoid prescribing of antibiotics to patients diagnosed with naso-
pharyngitis, acute upper respiratory tract infections (ARTI) or acute bronchitis.
Inappropriate prescribing of antibiotics to patients can lead to a rise in antibiotic-
resistant bacteria and subsequently increase the economic burden. The purpose of
this study was to determine the trends in the antibiotic prescribing rates for adults
diagnosed with nasopharyngitis, acute bronchitis or ARTIs in ambulatory care set-
tings in the United States after the 2006 guidelines. METHODS: This was a retro-
spective, cross-sectional analysis of the representative national survey of office
visits from theNational AmbulatoryMedical Care Survey for the years 2006 to 2008.
Adults18 years of age with a diagnosis of nasopharyngitis, ARTIs, or acute bron-
chitis were identified using International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes. Inappropriate antibiotic prescribing rates for the
three conditions were calculated separately and collectively. Descriptive analysis
was conducted to determine the utilization patterns by patient and physician char-
acteristics. Logistic regression was carried out to determine the trends in the anti-
biotic utilization. RESULTS: Analysis of multiyear data showed no statistically sig-
nificant trend (p-value  0.4622) in the antibiotic prescribing rates from 2006 to
2008. Approximately, 45.26 million office visits annually resulted in a primary di-
agnosis of nasopharyngitis, acuteURI, or acute bronchitis; of these visits, 1.5%, 44%,
and 61%, respectively, resulted in the prescribing of an antibiotic. Overall 47.26 % of
the study population was prescribed antibiotics. CONCLUSIONS: Antibiotic pre-
scription rate did not change significantly from 2006 to 2008. Antibiotics were pre-
scribed inappropriately in 47% of the adults diagnosedwith nasopharyngitis, ARTI,
or acute bronchitis. Concerted efforts are needed to improve antibiotic prescribing
practices for these conditions.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major public
health issue and is a leading cause ofmorbidity andmortality in the United States1.
High frequency of exacerbations can lead to the further decline in lung function in
patients with moderate to severe COPD2. The objectives of this study was to gain a
better understanding of short-acting and long-acting beta-agonist use (SABA and
LABA, respectively) in the inpatient setting and describe beta-agonist effects on
total cost and length of stay (LOS).METHODS:Data from the Premier Perspective™
Database, a US national representative hospital database, was used to identify the
study population, which included adults 40 and olderwith an inpatient visit having
a principal discharge diagnosis code of COPD (ICD-9-CM 491.xx, 492.xx, 496) be-
tween January 1, 2006 and March 31, 2010. RESULTS: There were 165,055 individ-
uals with a primary diagnosis code during an inpatient visit. The mean age for
SABA only users was 68.9 years and 67.7 years for LABA only users (p0.0001). The
majority of the patients were female (56.9% SABA only, 56.9% LABA only, p 
0.9988) and white (72.3% SABA only, 66.4% LABA only, p 0.0001). The unadjusted
mean total cost for LABAuserswas $5,727 compared to $7,084 for SABA (p0.0001).
LOSwas not different between LABA and SABAusers:mean 5.5 and 6.7 (p 0.4786).
Inpatientmortality for both beta-agonist user groupswas below two percent (1.50%
SABA versus 0.34% LABA, p  0.0001). CONCLUSIONS: Descriptive analyses indi-
cate there are some differences among individuals with COPD using only LABA use
compared to SABA only use during an inpatient visit. Modeling outcomes adjusting
for potential differences such as demographics and concomitant drug use will be
performed to further describe this population.
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OBJECTIVES: This study describes concomitant asthmamedication use in patients
treated with omalizumab (Xolair®), a monoclonal antibody indicated for moderate
to severe persistent allergic asthma. METHODS: An analysis of health insurance
claims from three large databases was conducted: MarketScan (1996-2009), Medic-
aid (1997-2009), and Wellpoint (2002-2010). Patients 12 years old newly initiated
on omalizumab with 12months of continuous insurance coverage prior to the first
omalizumab dispensing (baseline period) and 2 asthma claims were included.
Concomitant asthmamedication usewas summarized in eightmedication classes:
ICS, LABA, leukotriene modifiers, mast cell stabilizers, anticholinergics, SABA,
methylxanthines, and oral corticosteroids, according to the 2007 National Asthma
Education and Prevention Program guidelines for managing asthma. RESULTS: A
total 6,038 patients were identified (Medicaid: 731; MarketScan: 3,521; Wellpoint:
1,786). Mean age (SD) was 38.8 (12.6), 44.6 (14.0), and 47.3 (15.6), and males repre-
sented 31%, 36%, and 39% in Medicaid, MarketScan, andWellpoint, respectively. A
high proportion of new omalizumab users have had an asthma-related ER visit
(Medicaid: 34%; MarketScan: 17%; Wellpoint: 16%) or hospitalization (Medicaid:
36%; MarketScan: 14%; Wellpoint: 21%) prior to initiating omalizumab. The major-
ity of patients (Medicaid: 96%; MarketScan: 89%; Wellpoint: 86%) received three
concomitant asthma medication classes or more during the baseline period. Con-
comitant ICS use was observed in 95%, 89%, and 86% of Medicaid, MarketScan, and
Wellpoint patients, respectively. Only 1% of omalizumab users in Medicaid and 3%
in MarketScan and Wellpoint received no other asthma medication prior to initi-
ating omalizumab. CONCLUSIONS: Based on this large observational study using
health insurance claims from three databases, a minority (1-3%) of omalizumab
users receive monotherapy treatment for asthma.
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OBJECTIVES: Compare retrospective initial maintenance treatment (IMT) analyses
results from propensity matched (PM) comparisons to multiple regression (MR)
results (adjusted for treatment, demographics and pre-initiation comorbidities and
utilization). TheMRand PMmethods are twowidely usedmethods in observational
comparative outcome studies of pharmaceutical treatments to adjust for baseline
differences in non-randomized treatment populations, but research on the extent
to which study findingsmay differ between themethods is sparse.METHODS:One
year post-initiation cost differences and utilization outcomes (odds ratios (OR)/
incidence rate ratios (IRR) for emergency department visit (ED), hospitalization, or
combination of either ED or hospitalization) for subjects diagnosed with chronic
obstructive pulmonary disease (COPD) were reviewed using data (January 2004
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